Document registry — page 41
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low16 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) randomising 1,398 participants over 52 weeks. Primary result…
Moderate10 May 2023 -
Single-arm open-label, phase 1 study of Hexarelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in obesity randomising 338 participants over 48 weeks. Primary result: Mean change −24.2 % at…
Moderate09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 680 participants over 24 weeks. Primary result: Reduction of…
High09 May 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over single dose. Primary result: Marked growth-hormone release with attenuation on repeated administration.
Low09 May 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 May 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 May 2023 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gh axis over single dose. Primary result: Dose-dependent growth-hormone release without a measurable rise in…
Low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,098 participants over 52 weeks. Primary result: Superior to…
High04 May 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 1 diabetes (adjunct) randomising 480 participants over 52 weeks. Primary result: A…
Moderate01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over 8 weeks. Primary result: Higher antibody titres reported…
Moderate30 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low28 Apr 2023 -
Randomised crossover, phase 1 study of Semaglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low27 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low21 Apr 2023 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes and cardiovascular randomising 2,002 participants over median 85 weeks…
High20 Apr 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease randomising 576 participants over 52 weeks. Primary…
Low20 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low07 Apr 2023 -
Consultation on the policy governing the declaration and management of interests across the Institute, covering assessment committee members, external reviewers…
01 Apr 2023 -
Consultation on the policy governing what funding the Institute accepts, from whom, and on what published terms. The draft prohibits any funding arrangement that confers…
24 Mar 2023 -
Record of documents ratified in the 2023 Q1 assessment cycle.
18 Mar 2023 -
Glucose regulation impaired beyond normal limits but below diagnostic thresholds for diabetes, including impaired fasting glucose, impaired glucose tolerance, and…
16 Mar 2023 -
Degenerative joint disease of the knee with radiographic or symptomatic confirmation, occurring with obesity as a mechanical and inflammatory contributor.
09 Mar 2023
page 41 of 41